MediWound Ltd. (MDWD)

6.90
0.10 1.43
NASDAQ : Health Technology
Prev Close 7.00
Open 7.00
Day Low/High 6.90 / 7.00
52 Wk Low/High 3.56 / 8.25
Volume 8.60K
Avg Volume 35.00K
Exchange NASDAQ
Shares Outstanding 27.05M
Market Cap 186.63M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

MediWound priced an underwritten public offering of 4.4 million shares at $5 apiece.

MediWound's NexoBrid® Highlighted In 43 Presentations at The 17th European Burns Association Congress

MediWound's NexoBrid® Highlighted In 43 Presentations at The 17th European Burns Association Congress

Burn Experts from across Europe will share their NexoBrid Experience in 2 Plenary Sessions; 23 Oral Presentations and 18 Poster Presentations

MediWound Successfully Completes Second Cohort Of EscharEx® Phase 2 Study

MediWound Successfully Completes Second Cohort Of EscharEx® Phase 2 Study

Company intends to initiate EscharEx U.S. pivotal program in first half of 2018

BARDA Upsizes Contract With MediWound And Exercises Option To Fund Further NexoBrid® Indications

BARDA Upsizes Contract With MediWound And Exercises Option To Fund Further NexoBrid® Indications

Commits an Additional $32 Million to Support R&D Activities, Brings Total Non-Dilutive Funding to Up to $132 Million

MediWound Announces Changes To Its Board Of Directors

Enhances Board with Experienced Experts and Executives in U.S. Wound Care Market

MediWound Reports First Quarter 2017 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

MediWound's NexoBrid® And EscharEx® To Be Highlighted In Multiple Presentations At The Symposium On Advanced Wound Care Spring

Presentations Highlight the Benefits of Enzymatic Debridement

MediWound's NexoBrid® And EscharEx® To Be Highlighted In Presentations At The American Burn Association 49th Annual Meeting

Presentations Highlight the Benefits of Enzymatic Debridement with NexoBrid and EscharEx

Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid® In Burn Management Published In BioMed Research International

NexoBrid reduces average treatment costs by more than €5,000 compared with standard-of-care

MediWound Reports 2016 Fourth Quarter And Full Year Financial Results

Conference call begins today at 8:30 a.m. Eastern time

TheStreet Quant Rating: D- (Sell)